Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Myositis

• Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• OM336 in Seropositive Autoimmune Diseases
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
• GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
• GC012F in Patients With Autoimmune Diseases
• A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
• Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
• Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
• AlloNK, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
• Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
• A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies.
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
• Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
• Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
• A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
• A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
• IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
• A Phase 1 Study of ADI-001 in Autoimmune Disease
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
• Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
• Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained Rowers
• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
• The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and Erythropoiesis
• Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
• Add-on Intravenous Immunoglobulins in Early Myositis
• Myositis Interstitial Lung Disease Nintedanib Trial
• A Phase II/III Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
• A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
• Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Treatment of Idiopathic Inflammatory Myopathies
• A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
• Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study
• Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
• Phase III Trial of Sirolimus in IBM
• Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
• A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
• Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
• Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
• A Phase IIa Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
• Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
• Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
• Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
• Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
• Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease
• Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
• Study of Pioglitazone in Sporadic Inclusion Body Myositis
• Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
• Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
• Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
• Study of Arimoclomol in Inclusion Body Myositis (IBM)
• Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
• Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
• Natalizumab in Inclusion Body Myositis (IBM)
• Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
• Belimumab in Idiopathic Inflammatory Myositis
• Blood-flow Restricted Exercise in Inclusion Body Myositis
• Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
• Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
• Anakinra in Myositis
• A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
• The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
• Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
• Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
• Arimoclomol in Sporadic Inclusion Body Myositis
• Treatment With TNF Blockade, Infliximab, in Patients With Myositis
• Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
• Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
• Alemtuzumab to Treat Sporadic Inclusion Body Myositis
• Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies